IL183321A0 - Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof - Google Patents

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Info

Publication number
IL183321A0
IL183321A0 IL183321A IL18332107A IL183321A0 IL 183321 A0 IL183321 A0 IL 183321A0 IL 183321 A IL183321 A IL 183321A IL 18332107 A IL18332107 A IL 18332107A IL 183321 A0 IL183321 A0 IL 183321A0
Authority
IL
Israel
Prior art keywords
receptor
chromanylurea
compounds
inhibit vanilloid
subtype
Prior art date
Application number
IL183321A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL183321A0 publication Critical patent/IL183321A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL183321A 2004-11-24 2007-05-20 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof IL183321A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63063604P 2004-11-24 2004-11-24
PCT/US2005/042545 WO2006065484A2 (en) 2004-11-24 2005-11-22 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Publications (1)

Publication Number Publication Date
IL183321A0 true IL183321A0 (en) 2008-04-13

Family

ID=36588346

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183321A IL183321A0 (en) 2004-11-24 2007-05-20 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Country Status (13)

Country Link
US (2) US7812019B2 (enExample)
EP (2) EP1844038A2 (enExample)
JP (2) JP4932730B2 (enExample)
KR (2) KR101250824B1 (enExample)
CN (2) CN102161653A (enExample)
AU (1) AU2005316972B2 (enExample)
BR (1) BRPI0518581A2 (enExample)
CA (1) CA2588909A1 (enExample)
IL (1) IL183321A0 (enExample)
MX (1) MX2007006205A (enExample)
NZ (1) NZ555318A (enExample)
TW (1) TW200633712A (enExample)
WO (1) WO2006065484A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1954138B (zh) * 2004-03-02 2011-02-16 罗斯蒙德公司 具有改进电能产生的过程设备
US8538560B2 (en) 2004-04-29 2013-09-17 Rosemount Inc. Wireless power and communication unit for process field devices
US8145180B2 (en) * 2004-05-21 2012-03-27 Rosemount Inc. Power generation for process devices
KR101250824B1 (ko) * 2004-11-24 2013-04-05 아보트 러보러터리즈 바닐로이드 수용체 아형 1(ｖｒ1) 수용체를 억제하는크로마닐우레아 화합물 및 이의 용도
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
AR056320A1 (es) 2005-04-22 2007-10-03 Wyeth Corp Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
JP2009513659A (ja) * 2005-10-28 2009-04-02 アボット・ラボラトリーズ Ｔｒｐｖ１受容体を阻害するインダゾール誘導体
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
KR20080111144A (ko) * 2006-04-18 2008-12-22 아보트 러보러터리즈 바닐로이드 수용체 서브타입 １(ｖｒ１)의 길항제 및 이의 용도
US7913566B2 (en) 2006-05-23 2011-03-29 Rosemount Inc. Industrial process device utilizing magnetic induction
WO2008059339A2 (en) * 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Isoquinoline derivatives as vanilloid receptor modulators
CN101563318A (zh) * 2006-12-20 2009-10-21 艾博特公司 作为trpv1香草素受体拮抗剂用于治疗疼痛的n-(5,6,7,8-四氢萘-1-基)脲衍生物以及相关化合物
WO2008110863A1 (en) * 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
WO2009095726A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Acrylamide derivatives as vanilloid receptor 1 modulators
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
US8250924B2 (en) 2008-04-22 2012-08-28 Rosemount Inc. Industrial process device utilizing piezoelectric transducer
US8929948B2 (en) 2008-06-17 2015-01-06 Rosemount Inc. Wireless communication adapter for field devices
EP2310918B1 (en) * 2008-06-17 2014-10-08 Rosemount, Inc. Rf adapter for field device with variable voltage drop
US8694060B2 (en) 2008-06-17 2014-04-08 Rosemount Inc. Form factor and electromagnetic interference protection for process device wireless adapters
JP5554328B2 (ja) 2008-06-17 2014-07-23 ローズマウント インコーポレイテッド 本質安全の低電圧クランプ回路を備えるフィールド装置用ｒｆアダプタ
WO2010023512A1 (en) * 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
EP2352727A1 (en) * 2008-10-17 2011-08-10 Abbott Laboratories Trpv1 antagonists
JP2012505907A (ja) * 2008-10-17 2012-03-08 アボット・ラボラトリーズ Ｔｒｐｖ１拮抗薬
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN101654435B (zh) * 2009-06-09 2014-01-29 沈阳药科大学 N-苯甲基喹啉羧酸类化合物、组合物及其制备方法
US20100318007A1 (en) * 2009-06-10 2010-12-16 O'brien Donald J Electromechanical tactile stimulation devices and methods
US8626087B2 (en) 2009-06-16 2014-01-07 Rosemount Inc. Wire harness for field devices used in a hazardous locations
US9674976B2 (en) 2009-06-16 2017-06-06 Rosemount Inc. Wireless process communication adapter with improved encapsulation
JP2013502444A (ja) 2009-08-24 2013-01-24 アスセピオン ファーマスーティカル、インコーポレイテッド キナーゼ阻害剤としての５，６−ビシクロヘテロアリール含有尿素化合物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
US10761524B2 (en) 2010-08-12 2020-09-01 Rosemount Inc. Wireless adapter with process diagnostics
CA2831146C (en) 2011-03-25 2019-06-04 Abbvie Inc. Trpv1 antagonists
US9310794B2 (en) 2011-10-27 2016-04-12 Rosemount Inc. Power supply for industrial process field device
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096226A1 (en) * 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
CN109574972A (zh) * 2018-07-13 2019-04-05 郑州大学 一种3-烷基取代-4-色满酮类化合物及其制备方法
WO2022072741A1 (en) * 2020-09-30 2022-04-07 Katholieke Universiteit Leuven 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer
WO2025161263A1 (zh) * 2024-01-31 2025-08-07 深圳晶蛋生物医药科技有限公司 一种苯并吗啉类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8900565A (nl) 1989-03-08 1990-10-01 Philips Nv Methode voor de verwerking van een radio data signaal, alsmede ontvanger voor de uitvoering van deze methode.
IL93610A0 (en) * 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
EP0922028A1 (en) * 1996-08-26 1999-06-16 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
DE60036726T2 (de) * 1999-11-16 2008-02-07 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Harnstoff derivate als entzündungshemmende mittel
US6984647B2 (en) * 2002-05-17 2006-01-10 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid VR1 receptor
JP2006519806A (ja) * 2003-03-07 2006-08-31 グラクソ　グループ　リミテッド 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。
KR101250824B1 (ko) * 2004-11-24 2013-04-05 아보트 러보러터리즈 바닐로이드 수용체 아형 1(ｖｒ1) 수용체를 억제하는크로마닐우레아 화합물 및 이의 용도
JP2009513659A (ja) * 2005-10-28 2009-04-02 アボット・ラボラトリーズ Ｔｒｐｖ１受容体を阻害するインダゾール誘導体

Also Published As

Publication number Publication date
KR101250824B1 (ko) 2013-04-05
WO2006065484A2 (en) 2006-06-22
NZ555318A (en) 2011-01-28
JP4932730B2 (ja) 2012-05-16
KR20070086607A (ko) 2007-08-27
AU2005316972A1 (en) 2006-06-22
AU2005316972B2 (en) 2011-11-10
US20110152250A1 (en) 2011-06-23
EP1844038A2 (en) 2007-10-17
CN101443327A (zh) 2009-05-27
EP2527339A1 (en) 2012-11-28
BRPI0518581A2 (pt) 2008-11-25
TW200633712A (en) 2006-10-01
WO2006065484A3 (en) 2009-02-19
JP2008532925A (ja) 2008-08-21
JP2012111766A (ja) 2012-06-14
US20060128689A1 (en) 2006-06-15
KR20120137420A (ko) 2012-12-20
US8440691B2 (en) 2013-05-14
CA2588909A1 (en) 2006-06-22
MX2007006205A (es) 2009-02-13
CN102161653A (zh) 2011-08-24
US7812019B2 (en) 2010-10-12

Similar Documents

Publication Publication Date Title
IL183321A0 (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
ZA200808691B (en) Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
AP1916A (en) Purine compounds and use thereof as cannabinoid receptor ligands
EP1773871A4 (en) COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES
ZA200606313B (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
IL192426A0 (en) Prokineticin 2 receptor antagonists
IL192424A0 (en) Prokineticin 1 receptor antagonists
EP1814550A4 (en) ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1
ZA200710169B (en) Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists
DK1463759T3 (da) Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
IL179462A0 (en) Use of the receptor gpr86
EP2012779A4 (en) PROCESS FOR PREPARING INDAZOLYL UREES THAT INHIBIT VANILLOID RECEPTORS OF SUBTYPE 1 (VR1)
HK1111688A (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
EP1723145A4 (en) SUBSTITUTED 5,12-DIAZENZOANTHRACENANALOGA
ZA200705114B (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
EP1967519A4 (en) 3,4-DIHYDROBENZOXAZINE COMPOUND AND VANNILLLOID RECEPTOR 1 ACTIVITY INHIBITORS
GB2409587B (en) 'Kwicap'
IL179981A0 (en) Asymmetrically substituted biaryldiphosphine ligands 111
IL179980A0 (en) Asymmetrically substituted biaryldiphosphine ligands 1
HK1121956A (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
AU2003278113A8 (en) Stabilising agent mixture
ZA200804716B (en) 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (VR1) activity
HK1093728A (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
ZA200700361B (en) Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor
GB0420897D0 (en) Compounds and uses 3